Q4 Results 2025 Highlights: Dr Reddy’s profit rises by 21.95%; Swiggy loss widened to Rs 1081.18 core

- Gross NPA ratio at 3.27% improved by 171 bps YoY.

- Net NPA ratio at 0.82% improved by 40 bps YoY.

- PCR improved by 180 bps YoY and stands at 92.39%.

- Slippage Ratio for FY25 improved by 22 bps YoY and stands at 1.36%. Slippage Ratio for Q4FY25 improved by 6 bps YoY and stands at 0.32%.

- Credit Cost for FY25 improves by 2 bps YoY to 0.76%.

Bank of India on Friday released its fiscal fourth quarter earnings report with standalone profit at Rs 2625.91 crore, posting a jump of 82.49 per cent as compared to Rs 1438.91 crore recorded during the corresponding quarter of FY24. Net interest income (NII) stood at Rs 6063 crore, up 2.1 per cent on-year.

Dr Reddy’s Laboratories Ltd on Friday released its fiscal fourth quarter earnings report with profit at Rs 1593.90 crore, posting a growth of 21.95 per cent in comparison to Rs 1307.00 crore recorded during the corresponding quarter of FY24. It posted revenue from operations at Rs 8506.00 crore, up 20.09 per cent as against Rs 7083.00 crore recorded during the fourth quarter of previous financial year. The company EBITDA stood at Rs 2,975 crore.

Sriharsha Majety, MD & Group CEO, Swiggy, said, “FY25 was a year of many firsts for Swiggy. We launched multiple new apps, across Instamart, Snacc and recently, Pyng; all of which are aimed at opening up new user-segments and markets. Our Food delivery engine delivered best-ever results across innovation and execution, driving category-leading growth and rising profitability in lockstep. Quick-commerce is in a phase of rapid expansion and heightened competitive intensity, for which we have ramped-up investments aimed at market expansion (Megapods), reach (1000+ stores across 124 cities) and differentiation (Maxxsaver). Our Out of Home Consumption business turned profitable in Q4, within just 2 years of its integration. Overall, we remain focused on growth, on the back of delivering unparalleled convenience to consumers.”

Canara Bank posted a 20% beat on earnings at Rs50bn/1.3% RoA, mainly aided by treasury gains/recovery from written-off loans and provision reversal on SR investments. Credit growth outpaced expectations at 12.6% YoY/2.5% QoQ, while deposit growth was strong at 11% YoY/6.4% QoQ. This, coupled with higher loan yields, led to nearly flat NIMs at 2.7% after a steady fall for the past two quarters. Emkay Global said, “We raise earnings for FY26-28E by ~5-7%, factoring in the better treasury gains/NPA recoveries and lower LLP. Thus, we expect the bank to deliver 0.9-1.1% RoA over FY26- 28E. Key Risks: Slowdown in growth, lower margins due to macroeconomic challenges, and higher-than-expected increase in provisioning due to the ensuing ECL impact.”

The company board has recommended the final dividend of Rs 2.50 per equity share of Rs 5 each (i.e. 50 per cent) for the financial year 2024–2025 for approval of the Members of the Company at the ensuing annual general meeting.

The company board has recommended a dividend of Rs 65 (1300 per cent) per equity share of Rs 5 each for the year ended 31.03.2025. “The dividend, if approved by the members at the ensuing Annual General Meeting, will be dispatched / remitted within 30 days from the date of declaration,” it said.

CS Nopany, Executive Chairman, Sutlej Textiles and Industries Limited, said, “FY25 has been a challenging year due to ongoing global uncertainties, unpredictable demand, and changing trade and tariff rules. These external factors have impacted the entire textile industry, but they’ve also highlighted the need for resilience, flexibility, and strong operational management. At Sutlej Textiles, we have focused on strengthening our core — cutting costs, boosting efficiency, and building stronger relationships with customers in key markets. Although the earlier part of the year felt the impact of global challenges, our efforts are beginning to show, especially in Q4. Our team has worked hard to adjust supply chains, add more value to our products, and stay agile in response to changing market trends.”

The company board has recommended the final dividend of Rs 2.25 per Equity Share, being 22.50 per cent of the face value of Rs 10 each, for the financial year 2024-25 subject to the approval of the Shareholders of the company at the ensuing Annual General Meeting.

Elara Securities said, “Despite State-level issues by FY25-end, UBBL posted 5.6% YoY volume growth. Management has set beer volume growth target of 6-7% in the near term to be driven by premium segment growth (aims to achieve 25% market share). Amid an evolving outlook in KA and TL, the company expects growth in West and North India (reflective in Q4); thus, we expect a 12.5% sales CAGR during FY25-28E, sustaining our revenue estimates. Margin improvement hinges on portfolio premiumization and bottling collection efficiency, which warrant a gestation period; hence, we cut EBITDA by ~12% during FY26-27E.”

Kiran Mazumdar-Shaw, Chairperson, Biocon Group, said, “The Biocon Group ended the year with a strong performance across its businesses. The launch of Liraglutide in the UK market heralded our entry into the GLP-1 therapy segment. Our Biosimilars continue to build impressive shares in global markets with four biosimilars recording sales of USD 200 million each in FY25. This quarter marked the expansion of Syngene’s biologics manufacturing footprint through an acquisition of a state-of-the-art manufacturing facility in the U.S. FY25 has been a year of consolidation and transition. We are now on a path of accelerating growth with a commitment to innovation, digital augmentation and operational excellence.”

Biocon Ltd released its fiscal fourth quarter earnings report with profit at Rs 344.50 crore, posting a jump of 154.24 per cent in comparison to Rs 135.50 crore recorded during the corresponding quarter of FY24. It posted revenue from operations at Rs 4417.00 crore, up 12.76 per cent as against Rs 3917.10 crore recorded during the fourth quarter of previous financial year. Operating performance remained strong, with EBITDA rising 17.7 per cent YoY to Rs 1,078.2 crore.

Greetings! We, at FinancialExpress.com, are closely following the results announcements by companies across the sectors and are updating you with the key numbers and announcements by management on issues of interest. The fiscal fourth quarter earnings season is on and we will keep you updated on all the developments. Stay tuned.